MK0759
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuralgia, Postherpetic
Conditions
Neuralgia, Postherpetic
Trial Timeline
Nov 1, 2005 → Jan 1, 2007
NCT ID
NCT00245544About MK0759
MK0759 is a phase 2 stage product being developed by Merck for Neuralgia, Postherpetic. The current trial status is terminated. This product is registered under clinical trial identifier NCT00245544. Target conditions include Neuralgia, Postherpetic.
What happened to similar drugs?
8 of 18 similar drugs in Neuralgia, Postherpetic were approved
Approved (8) Terminated (3) Active (8)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00245544 | Phase 2 | Terminated |
Competing Products
20 competing products in Neuralgia, Postherpetic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + DS-5565 | Daiichi Sankyo | Pre-clinical | 26 |
| QUTENZA | Astellas Pharma | Approved | 43 |
| ASP8477 + Placebo | Astellas Pharma | Phase 2 | 35 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 35 |
| E2007 | Eisai | Phase 2/3 | 38 |
| KHK6188 + Placebo | Kyowa Kirin | Phase 2 | 35 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 39 |
| Galcanezumab | Eli Lilly | Approved | 43 |
| Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine | AbbVie | Phase 2 | 35 |
| MK-8291 + Placebo | Merck | Phase 1 | 29 |
| Etoricoxib + Placebo | Merck | Approved | 39 |
| Cetuximab + Placebo | Merck | Phase 2 | 35 |
| ADL5747 + Placebo + Pregabalin | Merck | Phase 2 | 27 |
| MK0686 | Merck | Phase 2 | 27 |
| Comparator: pregabalin + Comparator: Placebo (unspecified) | Merck | Phase 1 | 29 |
| EMA401 + Placebo | Novartis | Phase 2 | 27 |
| pregabalin | Pfizer | Approved | 43 |
| Lyrica (pregabalin) + Placebo | Pfizer | Approved | 43 |
| 2-weeks placebo then gabapentin + 1-week placebo then gabapentin | Pfizer | Pre-clinical | 26 |